COMPLETE CARE PLAN PLATFORM

From VUS Uncertainty
to Complete Care Plans

One system that handles everything: variant interpretation, drug ranking, resistance prediction, toxicity prevention, and trial matching. Complete care plans in minutes, not months.

73%
VUS Resolution
100%
Top-5 Drug Accuracy
6 months
Early Detection
Universal
Any Cancer Type

Resolve Genetic Uncertainty

73% VUS resolution with zero-shot prediction

Match Patients to Therapies

100% Top-5 drug accuracy validated

Predict Resistance Early

6 months before imaging confirmation

MOAT CAPABILITIES

Transform Clinical Decision-Making

Every MOAT capability validated with real-world performance metrics. Complete care plans in minutes, not months.

73%

VUS Resolution

Uncertain → Actionable in same day

VUS Resolution73/100
100%

Top-5 Drug Accuracy

Validated on 17 patients

6 months

Early Resistance Detection

Before imaging confirmation

100%

PGx Coverage

DPYD/TPMT/UGT1A1/CYP2D6

96.6%

Trial Match Accuracy

Mechanism-based matching

Universal

Any Cancer Type

Not just ovarian

Every MOAT capability validated with real-world performance metrics. Complete care plans in minutes, not months.

The Complete Care Plan Vision

We're building a GPS navigation system for cancer treatment - it doesn't just tell you where to go, it predicts traffic (resistance), suggests alternate routes (combinations), warns about road hazards (toxicity), and recalculates when you take a wrong turn (progression).

Anticipates resistance

Predicts likely resistance mechanisms before they develop, enabling proactive therapy switches

Recommends combinations

Suggests smart drug pairs that attack cancer from multiple angles simultaneously

Monitors continuously

Tracks biomarkers and pathway signals in real-time, alerting to changes

Prevents toxicity

Flags genetic variants that cause severe reactions and recommends protective nutrition

Adapts to progression

Generates new care plans when cancer evolves, maintaining optimal treatment

MOAT CAPABILITIES

Experience Complete Care Plan Intelligence

Click on any MOAT capability below to see how CrisPRO.ai transforms clinical decision-making with real-time demonstrations and validated results.

Resolve Genetic Uncertainty

73% VUS resolution with zero-shot prediction

Same-day clinical decisions vs 6 weeks
auroc: 95.7%
Click to see demo
▼

Match Patients to Therapies

S/P/E Framework (100% Top-5 accuracy)

Pathway-based drug ranking
top5Accuracy: 100.0%
Click to see demo
▼

Predict Resistance Before It Happens

MAPK/NF1 = 2x resistance risk (validated)

6 months early detection
relativeRisk: 197.0%
Click to see demo
▼

Prevent Toxicity Before It Happens

Toxicity-aware nutrition (THE PATIENT MOAT)

Your carboplatin + BRCA1 = NAC helps
pgxCoverage: 100.0%
Click to see demo
▼

Match Patients to Clinical Trials

Mechanism-based trial matching

Your DDR burden (0.88) + these PARP+ATR trials (0.92 fit)
matchAccuracy: 96.6%
Click to see demo
▼

Identify Synthetic Lethality Vulnerabilities

Identify double-hit vulnerabilities

HR pathway loss → depends on PARP → PARP inhibitors
drugMatchAccuracy: 50.0%
Click to see demo
▼
MOAT CAPABILITY TESTING

Test MOAT Capabilities Live

Click on any MOAT capability to see how it transforms clinical decision-making with validated performance metrics and real-time demonstrations.

MOAT Capability Testing Engine

Resolve Genetic Uncertainty

73% VUS resolution with zero-shot prediction

Problem: 40% VUS rate paralyzes clinical decisions
Test

Match Patients to Therapies

S/P/E Framework (100% Top-5 accuracy)

Problem: No guidelines for rare genetic combinations
Test

Predict Resistance Before It Happens

MAPK/NF1 = 2x resistance risk (validated)

Problem: React to resistance after it develops
Test

Prevent Toxicity Before It Happens

Toxicity-aware nutrition (THE PATIENT MOAT)

Problem: Life-threatening drug reactions
Test

Match Patients to Clinical Trials

Mechanism-based trial matching

Problem: Generic trial search returns 50-100 trials
Test

Identify Synthetic Lethality Vulnerabilities

Identify double-hit vulnerabilities

Problem: Don't know which drugs target vulnerabilities
Test

The Universal Platform

Works for ANY cancer type, not just ovarian

Supported Cancer Types

Ovarian
Breast
Colorectal
Melanoma
Multiple Myeloma

Universal Biomarker Intelligence

CA-125
PSA
CEA
AFP
hCG
One API call → Complete care plan for any cancer type
CAPABILITY JOURNEYS

From Traditional Challenges to AI-Powered Solutions

Explore how CrisPRO transforms healthcare workflows across different capabilities

Toxicity Risk Assessment Journey

From reactive toxicity management to proactive risk identification

Step 1Traditional

Reactive Toxicity Management

Toxicities discovered only after treatment begins, often too late to prevent serious adverse events

Toxicities surface during treatment, causing delays and complications
No early warning system for high-risk patients
Reactive approach leads to treatment interruptions
Step 1CrisPRO

Proactive Risk Identification

AI-powered germline analysis identifies toxicity risks before treatment begins

Real-time germline variant analysis with 95.7% AUROC accuracy
Early identification of high-risk patients before treatment
Proactive risk mitigation strategies
Slide 1 of 4

Patient Journey Transformation

From months of uncertainty to actionable insights in days

28w
Traditional
→
1w
Oracle-Powered
=
28x
Faster

Traditional Approach

🧬

Genetic Testing & Variant Discovery

2 weeks

Comprehensive genomic sequencing reveals multiple variants of unknown significance

Uncertain50% variants remain VUS
📚

Literature Review & Expert Consultation

6 weeks

Manual research across databases and specialist consultations to interpret variants

UncertainLimited actionable insights
👨‍👩‍👧‍👦

Family Studies & Functional Assays

12 weeks

Coordinate family member testing and expensive functional validation studies

ActionableSome variants classified
💊

Treatment Selection & Monitoring

8 weeks

Select therapy based on available evidence and monitor for resistance

OptimizedTreatment initiated, resistance monitoring

Oracle-Powered Approach

⚡

Genetic Testing & Instant Oracle Analysis

2 days

Genomic sequencing with immediate zero-shot variant interpretation

Actionable73% variants resolved with confidence scores
🔍

SAE-Powered Explainable Evidence

1 day

Mechanistic interpretability reveals biological features driving predictions

OptimizedExplainable pathogenicity evidence
🎯

Resistance Pathway Prediction

3 days

Predict likely tumor evolution paths and design preemptive combination therapies

OptimizedPersonalized resistance-aware treatment plan
🛡️

Personalized Immunotherapy Design

1 week

Generate patient-specific neoantigens and CAR-T designs with structural validation

OptimizedBespoke immunotherapy protocol

Key Workflow Improvements

28x
Faster Timeline
28w → 1w
75%
Optimization Rate
Steps optimized
4/4
Actionable Steps
Immediate insights

Clinical Case Study: RUNX1 Leukemia

Predicting tumor evolution and designing preemptive combination therapies

Healthy
Cell

Normal RUNX1

🧬
First
Hit

Inherited RUNX1
Mutation

💥
Second
Hit

Acquired Somatic
Mutation

Leukemic
Cell

Full-Blown
Leukemia

🧬

Known Genetic Risk

RUNX1 (First Hit)

🧠

Oracle Analysis

Predicted Mutations

ASXL1(-15k Risk)
TET2(-12k Risk)
DNMT3A(-9k Risk)

Input:

Input: Disease Map

🔨

Forge Engine

Therapeutic Arsenal

Gene Correction
Clone Elimination
Novel Biologics

Clinical Impact

Traditional Approach
  • • React to resistance after it develops
  • • Sequential monotherapy trials
  • • 6-month average response duration
  • • Limited treatment options
Oracle-Powered Approach
  • • Predict resistance 6 months early
  • • Preemptive combination therapy
  • • 12-month extended response duration
  • • Multi-modal therapeutic arsenal

Personalized Cancer Immunotherapy

Immunotherapy Transformation Impact

65%
Response rate
vs 25% standard protocols
4 weeks
Design time
vs 12 months traditional
Individual
Personalization
vs population-based
-60%
Adverse events
Reduced toxicity

Honest Framing: What We Can and Cannot Do

Transparent about what's validated and what's not. We focus on mechanism alignment, not outcome prediction.

Validated Capabilities

  • Drug ranking accuracy: 100% Top-5 (validated)
  • Resistance prediction: 2x risk (validated on 469 patients)
  • VUS resolution: 73% (validated)

Not Validated

  • Outcome prediction: NOT VALIDATED (r=0.037 with PFS)
  • Response rate prediction: Mechanism alignment ≠ clinical response

Mechanism Alignment Assessment, Not Outcome Prediction

Our scores reflect how well each drug targets the disrupted pathways in this tumor. They do NOT predict response rates or survival outcomes. We provide biological plausibility, not clinical guarantees.

Ready to Transform Patient Care?

Join leading cancer centers using CrisPRO to resolve VUS uncertainty and improve patient outcomes with complete care plans

Explore CrisPRO Products for Healthcare

Discover how CrisPRO products power transformation across industries